Andy Levitt of HealthTalker checks in with a report from day 2 of the DTC Perspectives conference in New Jersey.
I had to laugh. And you would, too.
I looked around the room as the clock approached noon today during Day 2 of the Fall DTC Perspectives conference. I was amazed by the amount of distraction that [...]

[Read more →]

In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough.
He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head of [...]

[Read more →]

There’s a lot of talk these days about India and China as potential markets and as sources for cheap manufacturing and R&D. But the real potential of these countries is far more interesting: As China and India (and Brazil, Russia, and Korea) learn to create new products, they’re going to do it at price [...]

[Read more →]

The big news this week—and, for that matter, this year—is Roche’s offer to buy the 44 percent of Genentech that it doesn’t already own. The blogosphere is burning with all the predictable predictions, dire and otherwise, attendant on a big pharma takeover of a biotech. The phrase “killing the goose that’s been laying the golden [...]

[Read more →]